Randomized phase III trial in extensive-disease small cell lung cancer comparing first-line etoposide to topotecan in combination with platinum.

Mau-Soerensen, Morten; Hansen, Olfred; Holm, Bente; Nyhus, Christa Haugaard; McCulloch, Tine; Nielsen, Henrik Anker; Wedervang, Kim; Rytter, Carsten; Jeppesen, Nina; Langer, Seppo W.

doi:10.1200/jco.2014.32.15_suppl.7519

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of AEs among treatment‐experienced patients receiving avelumab was obtained from the JAVELIN Merkel 200 trial. For comparator regimens, the incidence rates of AEs were sourced from appropriate published literature 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 and validated by clinicians. It was assumed that AE rates for treatment‐naïve and treatment‐experienced patients were the same.…”

Section: Methodsmentioning

confidence: 99%

“…The maximum duration of treatment for each chemotherapy regimen was sourced from published literature. 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 The first method used to model ToT was fitting parametric model of Kaplan‐Meier survival curve. The second method involved seeking clinical expert opinion to establish how avelumab would be expected to be administered in clinical practice, particularly in the long term.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A cost‐utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan

et al. 2021

View full text Add to dashboard Cite

Background: Metastatic Merkel cell carcinoma (mMCC) has traditionally been managed with palliative chemotherapy regimens or best supportive care (BSC). Avelumab, a novel anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody for mMCC treatment, is being studied in the pivotal JAVELIN Merkel 200 trial.Aim: Incorporating trial results, this analysis aimed to evaluate the cost-utility of avelumab in Taiwan.Methods and results: A de novo partitioned-survival model with three key health states related to survival (progression-free disease, progressed disease, and death) was applied in this study. The data of clinical efficacy, safety, and patient utilities were obtained from the JAVELIN Merkel 200 trial, literature review, and Taiwanese clinical expert opinion.Cost-utility analysis was performed, and results were presented as cost per qualityadjusted life year (QALY) gained. For treatment-naïve patients, the incremental costeffectiveness ratios (ICERs) for avelumab vs BSC and avelumab vs chemotherapy were US$44885.06 and US$42993.06 per QALY gained, respectively. As to treatmentexperienced mMCC patients, avelumab was associated with ICERs of US$27243.06 (vs BSC)/US$26557.43 (vs chemotherapy) per QALY gained. All ICERs remained consistently within the willingness-to-pay (WTP) threshold of US$53,333.33 per QALY gained. Conclusion:This study demonstrated avelumab to be a cost-effective treatment option for both treatment-experienced and treatment-naïve mMCC patients with very poor prognosis in Taiwan.

show abstract